CN116133661A - 淀粉样变性的治疗 - Google Patents

淀粉样变性的治疗 Download PDF

Info

Publication number
CN116133661A
CN116133661A CN202180060027.8A CN202180060027A CN116133661A CN 116133661 A CN116133661 A CN 116133661A CN 202180060027 A CN202180060027 A CN 202180060027A CN 116133661 A CN116133661 A CN 116133661A
Authority
CN
China
Prior art keywords
unsubstituted
substituted
group
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180060027.8A
Other languages
English (en)
Chinese (zh)
Inventor
凯文·杜安·邦克
艾哈迈德·阿布迪·萨玛塔
约瑟夫·罗伯特·平奇曼
黄琴华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ricoram Ip Holding Co ltd
Original Assignee
Ricoram Ip Holding Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ricoram Ip Holding Co ltd filed Critical Ricoram Ip Holding Co ltd
Publication of CN116133661A publication Critical patent/CN116133661A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • External Artificial Organs (AREA)
CN202180060027.8A 2020-05-19 2021-05-17 淀粉样变性的治疗 Pending CN116133661A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063027194P 2020-05-19 2020-05-19
US63/027,194 2020-05-19
PCT/US2021/032808 WO2021236543A1 (en) 2020-05-19 2021-05-17 Treatment for amyloidosis

Publications (1)

Publication Number Publication Date
CN116133661A true CN116133661A (zh) 2023-05-16

Family

ID=78708017

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180060027.8A Pending CN116133661A (zh) 2020-05-19 2021-05-17 淀粉样变性的治疗

Country Status (12)

Country Link
US (1) US20230210846A1 (https=)
EP (1) EP4138837A4 (https=)
JP (1) JP2023527741A (https=)
KR (1) KR20230013102A (https=)
CN (1) CN116133661A (https=)
AU (1) AU2021273731A1 (https=)
BR (1) BR112022023486A2 (https=)
CA (1) CA3183746A1 (https=)
IL (1) IL298297A (https=)
MX (1) MX2022014468A (https=)
TW (1) TW202207931A (https=)
WO (1) WO2021236543A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023114877A1 (en) * 2021-12-15 2023-06-22 Recurium Ip Holdings, Llc Triple therapy combinations of bcl-2 inhibitors, wee-1 inhibitors and other chemotherapeutic agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200108301A (ko) * 2018-01-10 2020-09-17 리커리엄 아이피 홀딩스, 엘엘씨 벤즈아미드 화합물
WO2019199899A1 (en) * 2018-04-09 2019-10-17 Case Western Reserve University Bioink and crosslinkable support medium for printing
US10659731B2 (en) * 2018-04-10 2020-05-19 Facebook, Inc. Automated cinematic decisions based on descriptive models
CA3095513A1 (en) * 2018-04-10 2019-10-17 DDP Specialty Electronic Materials US, Inc. Dispenser for can with fixed valve stem housing

Also Published As

Publication number Publication date
MX2022014468A (es) 2023-02-09
IL298297A (en) 2023-01-01
JP2023527741A (ja) 2023-06-30
BR112022023486A2 (pt) 2023-01-10
EP4138837A4 (en) 2024-05-22
CA3183746A1 (en) 2021-11-25
AU2021273731A1 (en) 2022-12-15
EP4138837A1 (en) 2023-03-01
WO2021236543A1 (en) 2021-11-25
TW202207931A (zh) 2022-03-01
KR20230013102A (ko) 2023-01-26
US20230210846A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
CN115135325B (zh) 组合
CA3165382A1 (en) Combinations
JP7794448B2 (ja) 組み合わせ
CN115867551A (zh) 单一疗法和组合疗法
KR20220034805A (ko) Bcl-2 단백질 억제제
CN115038450A (zh) 组合
JP2023508328A (ja) 組み合わせ
CN116133661A (zh) 淀粉样变性的治疗
CN115023229A (zh) 组合
CN116744919A (zh) Bcl-2抑制剂与化疗药的组合
CN115103673A (zh) 组合
RU2853597C1 (ru) Моно- и комбинированная терапия
CN115666574A (zh) 组合
CN115023228A (zh) 组合

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination